These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 14736604)

  • 1. [Raloxifene and breast: from the SERMs concept to its place in clinical practice].
    This P; Guyot B
    Gynecol Obstet Fertil; 2004 Jan; 32(1):75-84. PubMed ID: 14736604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
    Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
    Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
    Dunn BK; Ford LG
    Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for raloxifene use in daily clinical practice in the Swiss setting.
    Lippuner K; Buchard PA; De Geyter C; Imthurn B; Lamy O; Litschgi M; Luzuy F; Schiessl K; Stute P; Birkhäuser M
    Eur Spine J; 2012 Dec; 21(12):2407-17. PubMed ID: 22739699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Specific estrogen receptor modulators (SERMs)].
    Trémollières F; Lopes P
    Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
    Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
    Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Selective estrogen-receptor modulators (SERM's) in postmenopausal women].
    Hart W; Netelenbos JC
    Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1771-6. PubMed ID: 10494328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.
    Zujewski J
    Environ Mol Mutagen; 2002; 39(2-3):264-70. PubMed ID: 11921197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.
    Ko SS; Jordan VC
    Expert Opin Pharmacother; 2011 Mar; 12(4):657-74. PubMed ID: 21294695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiestrogens: clinical applications of pharmacology.
    Jordan VC
    J Soc Gynecol Investig; 2000; 7(1 Suppl):S47-8. PubMed ID: 10732329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D; Spencer CM
    Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raloxifene: a review of its use in the prevention of invasive breast cancer.
    Moen MD; Keating GM
    Drugs; 2008; 68(14):2059-83. PubMed ID: 18778124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
    Dickler MN; Norton L
    Ann N Y Acad Sci; 2001 Dec; 949():134-42. PubMed ID: 11795345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis].
    Pfeilschifter J
    Orthopade; 2001 Jul; 30(7):462-72. PubMed ID: 11515185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of raloxifene and its clinical applications in osteoporosis.
    Maricic M; Gluck O
    Expert Opin Pharmacother; 2002 Jun; 3(6):767-75. PubMed ID: 12036416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis.
    Fontana A; Delmas PD
    Endocrinol Metab Clin North Am; 2003 Mar; 32(1):219-32. PubMed ID: 12699300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.